Zhenyan Ye, Ying Kou, Jiaqi Shen, Jun Dang, Xiaofei Tan, Xiao Jiang, Xiaoxiong Wang, Hao Lu, Shirong Chen, Zhuzhong Cheng
{"title":"新诊断前列腺癌的 18F-PSMA-1007 PET/CT 和盆腔 MRI 比较研究。","authors":"Zhenyan Ye, Ying Kou, Jiaqi Shen, Jun Dang, Xiaofei Tan, Xiao Jiang, Xiaoxiong Wang, Hao Lu, Shirong Chen, Zhuzhong Cheng","doi":"10.1186/s12880-024-01376-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the difference in the diagnostic efficacy of <sup>18</sup>F-PSMA-1007 PET/CT and pelvic MRI in primary prostate cancer, as well as the correlation between the two methods and histopathological parameters and serum PSA levels.</p><p><strong>Methods: </strong>A total of 41 patients with suspected prostate cancer who underwent <sup>18</sup>F-PSMA-1007 PET/CT imaging in our department from 2018 to 2023 were retrospectively collected. All patients underwent <sup>18</sup>F-PSMA-1007 PET/CT and MRI scans. The sensitivity, PPV and diagnostic accuracy of MRI and <sup>18</sup>F-PSMA-1007 PET/CT in the diagnosis of prostate cancer were calculated after comparing the results of MRI and <sup>18</sup>F-PSMA-1007 PET/CT with biopsy. The Spearman test was used to calculate the correlation between <sup>18</sup>F-PSMA-1007 PET/CT, MRI parameters, histopathological indicators, and serum PSA levels.</p><p><strong>Results: </strong>Compared with histopathological results, the sensitivity, PPV and diagnostic accuracy of <sup>18</sup>F-PSMA-1007 PET/CT in the diagnosis of prostate cancer were 95.1%, 100.0% and 95.1%, respectively. The sensitivity, PPV and diagnostic accuracy of MRI in the diagnosis of prostate cancer were 82.9%, 100.0% and 82.9%, respectively. There was a mild to moderately positive correlation between Gleason (Gs) score, Ki-67 index, serum PSA level and <sup>18</sup>F-PSMA-1007 PET/CT parameters (p < 0.05). There was a moderately negative correlation between the expression of AMACR (P504S) and <sup>18</sup>F-PSMA-1007 PET/CT parameters (p < 0.05). The serum PSA level and the Gs score were moderately positively correlated with the MRI parameters (p < 0.05). There was no correlation between histopathological parameters and MRI parameters (p > 0.05).</p><p><strong>Conclusion: </strong>Compared with MRI, <sup>18</sup>F-PSMA-1007 PET/CT has higher sensitivity and diagnostic accuracy in the detection of malignant prostate tumors. In addition, the Ki-67 index and AMACR (P504S) expression were only correlated with <sup>18</sup>F-PSMA-1007 PET/CT parameters. Gs score and serum PSA level were correlated with <sup>18</sup>F-PSMA-1007 PET/CT and MRI parameters. <sup>18</sup>F-PSMA-1007 PET/CT examination can provide certain reference values for the clinical diagnosis, evaluation, and treatment of malignant prostate tumors.</p>","PeriodicalId":9020,"journal":{"name":"BMC Medical Imaging","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290235/pdf/","citationCount":"0","resultStr":"{\"title\":\"A comparative study of <sup>18</sup>F-PSMA-1007 PET/CT and pelvic MRI in newly diagnosed prostate cancer.\",\"authors\":\"Zhenyan Ye, Ying Kou, Jiaqi Shen, Jun Dang, Xiaofei Tan, Xiao Jiang, Xiaoxiong Wang, Hao Lu, Shirong Chen, Zhuzhong Cheng\",\"doi\":\"10.1186/s12880-024-01376-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the difference in the diagnostic efficacy of <sup>18</sup>F-PSMA-1007 PET/CT and pelvic MRI in primary prostate cancer, as well as the correlation between the two methods and histopathological parameters and serum PSA levels.</p><p><strong>Methods: </strong>A total of 41 patients with suspected prostate cancer who underwent <sup>18</sup>F-PSMA-1007 PET/CT imaging in our department from 2018 to 2023 were retrospectively collected. All patients underwent <sup>18</sup>F-PSMA-1007 PET/CT and MRI scans. The sensitivity, PPV and diagnostic accuracy of MRI and <sup>18</sup>F-PSMA-1007 PET/CT in the diagnosis of prostate cancer were calculated after comparing the results of MRI and <sup>18</sup>F-PSMA-1007 PET/CT with biopsy. The Spearman test was used to calculate the correlation between <sup>18</sup>F-PSMA-1007 PET/CT, MRI parameters, histopathological indicators, and serum PSA levels.</p><p><strong>Results: </strong>Compared with histopathological results, the sensitivity, PPV and diagnostic accuracy of <sup>18</sup>F-PSMA-1007 PET/CT in the diagnosis of prostate cancer were 95.1%, 100.0% and 95.1%, respectively. The sensitivity, PPV and diagnostic accuracy of MRI in the diagnosis of prostate cancer were 82.9%, 100.0% and 82.9%, respectively. There was a mild to moderately positive correlation between Gleason (Gs) score, Ki-67 index, serum PSA level and <sup>18</sup>F-PSMA-1007 PET/CT parameters (p < 0.05). There was a moderately negative correlation between the expression of AMACR (P504S) and <sup>18</sup>F-PSMA-1007 PET/CT parameters (p < 0.05). The serum PSA level and the Gs score were moderately positively correlated with the MRI parameters (p < 0.05). There was no correlation between histopathological parameters and MRI parameters (p > 0.05).</p><p><strong>Conclusion: </strong>Compared with MRI, <sup>18</sup>F-PSMA-1007 PET/CT has higher sensitivity and diagnostic accuracy in the detection of malignant prostate tumors. In addition, the Ki-67 index and AMACR (P504S) expression were only correlated with <sup>18</sup>F-PSMA-1007 PET/CT parameters. Gs score and serum PSA level were correlated with <sup>18</sup>F-PSMA-1007 PET/CT and MRI parameters. <sup>18</sup>F-PSMA-1007 PET/CT examination can provide certain reference values for the clinical diagnosis, evaluation, and treatment of malignant prostate tumors.</p>\",\"PeriodicalId\":9020,\"journal\":{\"name\":\"BMC Medical Imaging\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290235/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Medical Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12880-024-01376-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medical Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12880-024-01376-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
A comparative study of 18F-PSMA-1007 PET/CT and pelvic MRI in newly diagnosed prostate cancer.
Purpose: To evaluate the difference in the diagnostic efficacy of 18F-PSMA-1007 PET/CT and pelvic MRI in primary prostate cancer, as well as the correlation between the two methods and histopathological parameters and serum PSA levels.
Methods: A total of 41 patients with suspected prostate cancer who underwent 18F-PSMA-1007 PET/CT imaging in our department from 2018 to 2023 were retrospectively collected. All patients underwent 18F-PSMA-1007 PET/CT and MRI scans. The sensitivity, PPV and diagnostic accuracy of MRI and 18F-PSMA-1007 PET/CT in the diagnosis of prostate cancer were calculated after comparing the results of MRI and 18F-PSMA-1007 PET/CT with biopsy. The Spearman test was used to calculate the correlation between 18F-PSMA-1007 PET/CT, MRI parameters, histopathological indicators, and serum PSA levels.
Results: Compared with histopathological results, the sensitivity, PPV and diagnostic accuracy of 18F-PSMA-1007 PET/CT in the diagnosis of prostate cancer were 95.1%, 100.0% and 95.1%, respectively. The sensitivity, PPV and diagnostic accuracy of MRI in the diagnosis of prostate cancer were 82.9%, 100.0% and 82.9%, respectively. There was a mild to moderately positive correlation between Gleason (Gs) score, Ki-67 index, serum PSA level and 18F-PSMA-1007 PET/CT parameters (p < 0.05). There was a moderately negative correlation between the expression of AMACR (P504S) and 18F-PSMA-1007 PET/CT parameters (p < 0.05). The serum PSA level and the Gs score were moderately positively correlated with the MRI parameters (p < 0.05). There was no correlation between histopathological parameters and MRI parameters (p > 0.05).
Conclusion: Compared with MRI, 18F-PSMA-1007 PET/CT has higher sensitivity and diagnostic accuracy in the detection of malignant prostate tumors. In addition, the Ki-67 index and AMACR (P504S) expression were only correlated with 18F-PSMA-1007 PET/CT parameters. Gs score and serum PSA level were correlated with 18F-PSMA-1007 PET/CT and MRI parameters. 18F-PSMA-1007 PET/CT examination can provide certain reference values for the clinical diagnosis, evaluation, and treatment of malignant prostate tumors.
期刊介绍：
BMC Medical Imaging is an open access journal publishing original peer-reviewed research articles in the development, evaluation, and use of imaging techniques and image processing tools to diagnose and manage disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
